ReviewCurrent hematologic malignancy reports2023
A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases.
Andrea Duminuco et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
23 papers cite it
this paperpooled itcites it